{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:43:25Z","timestamp":1791924205810,"version":"4.3.4"},"reference-count":44,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports\u00ae"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ekir.2025.10.018","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:12:44Z","timestamp":1761869564000},"page":"32-42","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Infliximab for Grade III or IV Immune Checkpoint Inhibitor Nephritis Clinical and Translational Evidence"],"prefix":"10.1016","volume":"11","author":[{"given":"Nada","family":"Youssef","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masroor","family":"Habeeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zainab","family":"Alhamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Mamlouk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valda","family":"Page","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Tchakarov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sreyashi","family":"Basu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adi","family":"Diab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Padmanee","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ala","family":"Abudayyeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2025.10.018_bib1","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.2215\/CJN.00990119","article-title":"The incidence, causes, and risk factors of acute kidney injury in patients receiving immune checkpoint inhibitors","volume":"14","author":"Seethapathy","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.10.018_bib2","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003467","article-title":"Acute kidney injury in patients treated with immune checkpoint inhibitors","volume":"9","author":"Gupta","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ekir.2025.10.018_bib3","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ekir.2020.10.002","article-title":"A systematic review of immune checkpoint inhibitor-associated glomerular disease","volume":"6","author":"Kitchlu","year":"2021","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2025.10.018_bib4","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ekir.2025.10.018_bib5","doi-asserted-by":"crossref","first-page":"582","DOI":"10.6004\/jnccn.2024.0057","article-title":"NCCN guidelines(R) insights: management of immunotherapy-related toxicities","volume":"22","author":"Thompson","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ekir.2025.10.018_bib6","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.kint.2016.04.008","article-title":"Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors","volume":"90","author":"Cortazar","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.10.018_bib7","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.kint.2019.07.022","article-title":"Immune checkpoint inhibitor nephrotoxicity: what do we know and what should we do?","volume":"97","author":"Perazella","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.10.018_bib8","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1038\/ki.2010.89","article-title":"Acute interstitial nephritis","volume":"77","author":"Praga","year":"2010","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.10.018_bib9","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/ckj\/sfw024","article-title":"Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma","volume":"9","author":"Murakami","year":"2016","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ekir.2025.10.018_bib10","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.ekir.2022.11.020","article-title":"Cytokines and immune cell phenotype in acute kidney injury associated with immune checkpoint inhibitors","volume":"8","author":"Farooqui","year":"2023","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2025.10.018_bib11","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1877415","article-title":"Infliximab for the treatment of patients with checkpoint inhibitor-associated acute tubular interstitial nephritis","volume":"10","author":"Lin","year":"2021","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ekir.2025.10.018_bib12","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.127456","article-title":"Urine TNF-alpha and IL-9 for clinical diagnosis of acute interstitial nephritis","volume":"4","author":"Moledina","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.ekir.2025.10.018_bib13","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1093\/ndt\/gfae257","article-title":"Biomarker-guided infliximab therapy for immune checkpoint inhibitor-induced acute interstitial nephritis","volume":"40","author":"Barbir","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2025.10.018_bib14","series-title":"Wiley Series in Probability and Statistics","first-page":"677","article-title":"Statistical methods for the analysis of biomedical data","author":"Woolson","year":"2002"},{"key":"10.1016\/j.ekir.2025.10.018_bib15","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric-estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.ekir.2025.10.018_bib16","first-page":"163","article-title":"Evaluation of survival data and two new rank order statistics arising in its consideration","volume":"50","author":"Mantel","year":"1966","journal-title":"Cancer Chemother Rep"},{"key":"10.1016\/j.ekir.2025.10.018_bib17","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life-tables","volume":"34","author":"Cox","year":"1972","journal-title":"J R Stat Soc B"},{"key":"10.1016\/j.ekir.2025.10.018_bib18","doi-asserted-by":"crossref","first-page":"6375","DOI":"10.1038\/s41467-021-26415-4","article-title":"Pilot study of tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma","volume":"12","author":"Campbell","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.ekir.2025.10.018_bib19","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/ckj\/sfw058","article-title":"Erratum: severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma","volume":"9","author":"Murakami","year":"2016","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ekir.2025.10.018_bib20","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/S0140-6736(00)04954-0","article-title":"Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial","volume":"357","author":"Chaudhari","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2025.10.018_bib21","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1038\/nm939","article-title":"Lasker clinical medical research award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases","volume":"9","author":"Feldmann","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.ekir.2025.10.018_bib22","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1136\/gut.2003.018515","article-title":"Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County","volume":"53","author":"Ljung","year":"2004","journal-title":"Gut"},{"key":"10.1016\/j.ekir.2025.10.018_bib23","doi-asserted-by":"crossref","first-page":"5181","DOI":"10.3390\/cancers15215181","article-title":"Infliximab for treatment of immune adverse events and its impact on tumor response","volume":"15","author":"Parvathareddy","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ekir.2025.10.018_bib24","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1007\/s10067-006-0357-4","article-title":"Isolated renal sarcoidosis: a rare presentation of a rare disease treated with infliximab","volume":"26","author":"Ahmed","year":"2007","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.ekir.2025.10.018_bib25","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1053\/j.ajkd.2004.10.011","article-title":"Isolated sarcoid granulomatous interstitial nephritis responding to infliximab therapy","volume":"45","author":"Thumfart","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2025.10.018_bib26","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ekir.2025.10.018_bib27","doi-asserted-by":"crossref","first-page":"5267","DOI":"10.3390\/cancers14215267","article-title":"Pathologic predictors of response to treatment of immune checkpoint inhibitor-induced kidney injury","volume":"14","author":"Abudayyeh","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ekir.2025.10.018_bib28","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1038\/s41467-017-02358-7","article-title":"TNFalpha blockade overcomes resistance to anti-PD-1 in experimental melanoma","volume":"8","author":"Bertrand","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.ekir.2025.10.018_bib29","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/10552","article-title":"Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis","volume":"5","author":"Moore","year":"1999","journal-title":"Nat Med"},{"key":"10.1016\/j.ekir.2025.10.018_bib30","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1046\/j.1365-2133.2000.03539.x","article-title":"Role for tumour necrosis factor-alpha receptors in ultraviolet-induced skin tumours","volume":"142","author":"Starcher","year":"2000","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ekir.2025.10.018_bib31","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1593\/neo.111224","article-title":"Neutralization of tumor necrosis factor bioactivity ameliorates urethane-induced pulmonary oncogenesis in mice","volume":"13","author":"Karabela","year":"2011","journal-title":"Neoplasia"},{"key":"10.1016\/j.ekir.2025.10.018_bib32","first-page":"560","article-title":"Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis","volume":"118","author":"Popivanova","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ekir.2025.10.018_bib33","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1158\/1078-0432.CCR-19-3322","article-title":"Association of anti-TNF with decreased survival in steroid refractory ipilimumab and anti-PD1-treated patients in the Dutch melanoma treatment registry","volume":"26","author":"Verheijden","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ekir.2025.10.018_bib34","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003277","article-title":"Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study","volume":"9","author":"Zou","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ekir.2025.10.018_bib35","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1186\/s40425-019-0711-0","article-title":"Concurrent therapy with immune checkpoint inhibitors and TNFalpha blockade in patients with gastrointestinal immune-related adverse events","volume":"7","author":"Badran","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ekir.2025.10.018_bib36","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s40425-018-0412-0","article-title":"Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis","volume":"6","author":"Johnson","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ekir.2025.10.018_bib37","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/s41586-019-1162-y","article-title":"Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy","volume":"569","author":"Perez-Ruiz","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ekir.2025.10.018_bib38","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/CJI.0000000000000268","article-title":"Incidence and clinical impact of anti-TNFalpha treatment of severe immune checkpoint inhibitor-induced colitis in advanced melanoma: the Mecolit survey","volume":"42","author":"Lesage","year":"2019","journal-title":"J Immunother"},{"key":"10.1016\/j.ekir.2025.10.018_bib39","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1158\/1078-0432.CCR-20-3449","article-title":"Combining nivolumab and ipilimumab with infliximab or Certolizumab in patients with advanced melanoma: first results of a phase Ib clinical trial","volume":"27","author":"Montfort","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ekir.2025.10.018_bib40","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41416-020-0882-y","article-title":"Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way?","volume":"123","author":"Cheung","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ekir.2025.10.018_bib41","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000451","article-title":"Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis","volume":"8","author":"Mooradian","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ekir.2025.10.018_bib42","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1073\/pnas.87.3.1233","article-title":"Heritable major histocompatibility complex class II-associated differences in production of tumor necrosis factor alpha: relevance to genetic predisposition to systemic lupus erythematosus","volume":"87","author":"Jacob","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ekir.2025.10.018_bib43","doi-asserted-by":"crossref","first-page":"R545","DOI":"10.1186\/ar1715","article-title":"Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey","volume":"7","author":"De Bandt","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.ekir.2025.10.018_bib44","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1681\/ASN.2006050418","article-title":"Involvement of drug-specific T cells in acute drug-induced interstitial nephritis","volume":"17","author":"Spanou","year":"2006","journal-title":"J Am Soc Nephrol"}],"container-title":["Kidney International Reports\u00ae"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S246802492500662X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S246802492500662X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T10:31:04Z","timestamp":1773829864000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S246802492500662X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S246802492500662X"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2025.10.018","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Infliximab for Grade III or IV Immune Checkpoint Inhibitor Nephritis Clinical and Translational Evidence","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports\u00ae","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2025.10.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}